Specify a stock or a cryptocurrency in the search bar to get a summary
Shanghai MicuRx Pharmaceutical Co. Ltd. A
688373Shanghai MicuRx Pharmaceutical Co., Ltd., a biopharmaceutical company, discovers, develops, and commercialize drugs for unmet medical needs. It is developing Contezolid (MRX-I) and Contezoilid acefosamil (MRX-4) oxazolidinone antibiotics for multidrug-resistant gram-positive bacteria; MRX-8 MRX, a polymyxin antibiotic, to target multidrug-resistant Gram-negative bacteria; MRX-5 for multidrug-resistant gram-negative bacteria; MRX-7 for multidrug-resistant gram-positive bacteria; MRX-15 and MRX-17 to treat kidney disease; MRX-18 for the treatment of COVID-19; and MRX-23 for the treatment of tumour. Shanghai MicuRx Pharmaceutical Co., Ltd. was founded in 2007 and is headquartered in Shanghai, China. Address: 53, Edison Road, Shanghai, China
Analytics
WallStreet Target Price
49.73 CNYP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures 688373
Dividend Analytics 688373
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History 688373
Stock Valuation 688373
Financials 688373
Results | 2019 | Dynamics |